Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
He simply said it has never been discussed.
He said 4 submissions next year and approvals the following year. They could all end up being submitted in the back half of 2022. We haven’t heard of any study results so these are either submissions based on previous studies Elite has done (doubtful) or new ones. Elite typically needed 6 months from positive bioequivalency studies to submit the ANDA.
Also, still no agreement with Sungen on next antibiotic. No word from FDA yet on antibiotic submission either…
We won’t be there by this time next year either.
Heard it a few months ago. Beautiful song.
Nice to see the rev increase, but I think margins increased due to the revenue decrease. It was from margin mix. Less revenues from mfg and more from licensing drove the higher margins. We had about $1M less in mfg revs, which is the primarily driven by Adderall revenue. Not sure the higher margins are a good thing and certainly wouldn’t be sustainable. Was hoping otherwise and then I dove into the data.
Never ending fun:
In June 2021, the Company entered into a development and license agreement with Mikah Pharma LLC, pursuant to which Mikah Pharma LLC will engage in the research, development, sales and licensing of generic pharmaceutical products. In addition, Mikah Pharma LLC will collaborate to develop and commercialize generic products including formulation development, analytical method development, manufacturing, sales and marketing of generic products. Initially two generic products were identified for the parties to develop.
I agree. It’s taken 8 years to become close to consistent CFP under current mgmt. it will take several more to rebuild our R&D pipeline and execute on it, especially since they are focusing on generics.
5 years later and the company still doesn’t have the fundamentals to go to NASDAQ.
According to their financial statements they have yet to hit a penny in EPS.
If there is anything consistent about this stock, it is the number of red days if offers to investors.
Lots of selling before the next cc. Today’s market sentiments on ELTP about sums it up.
For months the ask just keeps getting lower and lower. I don’t think this is market maker manipulation. I find that an excuse. I think this is simply larger holders selling our because they don’t buy into management’s ability to move the company forward in a decent timeframe. Lots of strategies have simply fallen apart and not come to fruition. CFP is a great start (not there yet after last Qtr results), but after 8 years not sure that’s reason to celebrate or cry.
Agree 100%
I’m not sure that’s the case. Without any concrete movement in the company’s direction, the share price will continue to drop.
This is the (piss poor) song that never ends. It just goes on and on my friend…
I completely agree, but I think 12 months is generous. I’m expecting closer to 18-24, especially since all we new is Loxapine. Adderall launch is a dud.
I worry how much he’ll want for 50% Adderall ownership further diluting or burning cash reserves.
Hard part is that he is the major owner of the company.
Why weren’t they CFP last quarter?
You mean the bid that keeps getting lower by the day? No improvement in company = no new interest driving share price down as holders sell little by little.
Last Q was only $4.3M and hopefully will be the bottom of the downhill slide.
Why would you buy stock on a blog post?
Lol this was posted a year ago by another user and revenue has been trailing ever since.
How big of a market do they need to enter for the monster to get them fully cash flow positive? Billion dollar market for Adderall and yet still scraping by.
Management speaks regarding futurity because investing is forward looking. Stocks receive forward multiple benefits based on that future expected benefit from strategic execution. Honking generic horn doesn’t bring much.
Not that it matters, but TDA is often incorrect. They are directionally correct.
ASIN running fast away from any green close? Lol
Not sure how he can take it in cash without dilution. Company wasn’t cash flow positive last quarter.
If financials are poor, we may get the appropriately timed release next Friday after hours, otherwise I’d expect them on the 16th with a subsequent call the next day. An update is right around the corner…
Earnings about two weeks away. Hopefully CFP again. Last quarter was a debacle. Not even CFP for the quarter.
I assume revenue will tick back up from prior quarter. Not expecting a Y/Y increase. I’ll take that as a pleasant surprise if it does beat LY.
Careful on the fake news Mr I just created a new login today for this post
Lol I didn’t do any of that. We could also add review SEC filings for accuracy and how many times has Elite had to refile?
Except 20% usually gets you a seat at the table, not to eat the whole buffet.
Don’t forget, much of Elite is owned by CEO. He is by far the largest shareholder.
I used to work in IR, thanks for asking.
Lol this is what public companies do. They tell their story to the public shareholder base. This is what investor conferences are for, this is what investor says are for held by the company, this is why companies have relationships with sell side analysts, etc. This is the most foundational of any IR team, which makes me wonder what exactly is being done.
If it was a private company there would be no IR team and they would do nothing, which is what we have the equivalent of today.
One of the jobs of investor relations is to optimize the share price. They get the story out to the shareholder community, tell the story of the company, future direction, strategies, etc. This isn’t new. And yes, a company absolutely can influence their stock price. Elite simply chooses not to do so.
Shows the lack of work from IR in getting out the story or perhaps there is no story worth telling as of yet.
Trying to work on Adderall study from many many months ago, but Covid is delaying it. Nothing new
$5M total market for Loxapine is only “monster” to be added this year. No study results for ANDAs have been published so we are still many months away from any filings.